
New biologics have emerged as potential therapies for myasthenia gravis (MG), an autoimmune disease that involves antibodies attacking neuromuscular junction proteins. Promising results from two recent trials indicate the effectiveness and tolerability of zilucoplan, a complement C5 inhibitor, and rozanolixizumab, an FcRn inhibitor, in treating generalized MG patients. These findings suggest that these targeted therapies could provide valuable treatment options for individuals with MG, offering hope for improved management and outcomes in this challenging autoimmune condition.
Like
Save
Share